Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Pacific Biosciences Q3 Adj. EPS $(0.12) Beats $(0.15) Estimate, Sales $38.441M Miss $40.210M Estimate

Author: Benzinga Newsdesk | November 05, 2025 04:19pm
Pacific Biosciences (NASDAQ:PACB) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.15) by 22.58 percent. This is a 29.41 percent increase over losses of $(0.17) per share from the same period last year. The company reported quarterly sales of $38.441 million which missed the analyst consensus estimate of $40.210 million by 4.40 percent. This is a 3.82 percent decrease over sales of $39.967 million the same period last year.

Posted In: PACB


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist